Gastro hep advances · 2026
Recompensation in Patients With Alcohol-Related Liver Disease-A Multicenter Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kulkarni Anand V, Premkumar Madhumita, Kumar Karan, Roy Akash, Giri Suprabhat, Pasumarthy Ashirvad, Sharma Mithun, Venishetty Shantan, Iyengar Sowmya, Alla Manasa, Kalapala Rakesh, Rao Padaki Nagaraj, Reddy Duvvur Nageshwar, Singal Ashwani K, Reddy K Rajender
Аннотация
BACKGROUND AND AIMS: Removal of etiology of cirrhosis may lead to recompensation in decompensated cirrhosis. Few studies have reported on rates of recompensation, as per Baveno VII criteria, in viral etiology-related decompensated cirrhosis. Our aim was to assess the rate and predictors of recompensation in the spectrum of alcohol-related liver disease (ALD).
METHODS: Retrospective multicenter cohort study across 5 Indian centers included patients with a spectrum of ALD from January 2018 to November 2024. Clinical and biochemical data were collected and patients followed, and end points of recompensation, mortality, and transplant-free survival were evaluated.
RESULTS: Among 344 patients (age: 41.2 ± 8.4 years; Model for End-Stage Liver Disease: 23.9 ± 6.2; men: 98.3%), 242 had decompensated cirrhosis with alcohol-associated hepatitis (DC + AAH), and 102 had decompensated cirrhosis without alcohol-associated hepatitis (DC-AAH). Twenty percent (69/344) achieved recompensation as per Baveno VII criteria over 21 (range, 12-67) months. The recompensation rate was higher among those with DC-AAH (30.4%; 31/102) compared to DC + AAH (15.7%; 38/242; P = .002). Transplant-free survival was higher among those who recompensated (DC + AAH: 92.1% vs 77.9%; DC-AAH: 93.5% vs 76.1%). On competing risk regression analysis, duration of abstinence (subdistribution hazard ratio, 1.03 [95% confidence interval, 1.01-1.05]; P = .04) and Child score (subdistribution hazard ratio 0.83 [95% confidence interval, 0.71-0.98]; P = .03) predicted recompensation. Model for End-Stage Liver Disease (hazard ratio, 1.09 [1.09-1.16]; P = .001) and recompensation (hazard ratio, 0.14 [0.04-0.49]; P = .002) predicted mortality.
CONCLUSION: Twenty percent of patients in the spectrum of ALD demonstrated recompensation, which was associated with improved survival.
METHODS: Retrospective multicenter cohort study across 5 Indian centers included patients with a spectrum of ALD from January 2018 to November 2024. Clinical and biochemical data were collected and patients followed, and end points of recompensation, mortality, and transplant-free survival were evaluated.
RESULTS: Among 344 patients (age: 41.2 ± 8.4 years; Model for End-Stage Liver Disease: 23.9 ± 6.2; men: 98.3%), 242 had decompensated cirrhosis with alcohol-associated hepatitis (DC + AAH), and 102 had decompensated cirrhosis without alcohol-associated hepatitis (DC-AAH). Twenty percent (69/344) achieved recompensation as per Baveno VII criteria over 21 (range, 12-67) months. The recompensation rate was higher among those with DC-AAH (30.4%; 31/102) compared to DC + AAH (15.7%; 38/242; P = .002). Transplant-free survival was higher among those who recompensated (DC + AAH: 92.1% vs 77.9%; DC-AAH: 93.5% vs 76.1%). On competing risk regression analysis, duration of abstinence (subdistribution hazard ratio, 1.03 [95% confidence interval, 1.01-1.05]; P = .04) and Child score (subdistribution hazard ratio 0.83 [95% confidence interval, 0.71-0.98]; P = .03) predicted recompensation. Model for End-Stage Liver Disease (hazard ratio, 1.09 [1.09-1.16]; P = .001) and recompensation (hazard ratio, 0.14 [0.04-0.49]; P = .002) predicted mortality.
CONCLUSION: Twenty percent of patients in the spectrum of ALD demonstrated recompensation, which was associated with improved survival.